Trials / Active Not Recruiting
Active Not RecruitingNCT04846920
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)
A Phase 1, Dose-escalation Study to Evaluate Safety and Tolerability of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 52 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this study is to evaluate the safety, tolerability and pharmacokinetics of escalating doses of belzutifan as second line positive (2L+) treatment in participants with advanced clear cell renal cell carcinoma (ccRCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Belzutifan | 40 mg tablet administered orally at a dose of 160 mg, 200 mg, or 120 mg. |
Timeline
- Start date
- 2021-06-14
- Primary completion
- 2026-07-21
- Completion
- 2026-07-21
- First posted
- 2021-04-15
- Last updated
- 2024-11-22
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04846920. Inclusion in this directory is not an endorsement.